Arch Therapeutics, Inc.
ARTH
$0.20
$0.042627.07%
OTC PK
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.13% | -30.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.13% | -30.50% | |||
| Cost of Revenue | -2.31% | -8.47% | |||
| Gross Profit | -4.85% | -53.81% | |||
| SG&A Expenses | 28.16% | -47.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.83% | -41.02% | |||
| Operating Income | -16.52% | 41.35% | |||
| Income Before Tax | -284.91% | 45.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -284.91% | 45.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -284.91% | 45.22% | |||
| EBIT | -16.52% | 41.35% | |||
| EBITDA | -16.54% | 41.35% | |||
| EPS Basic | -339.73% | 42.65% | |||
| Normalized Basic EPS | -289.42% | 42.64% | |||
| EPS Diluted | -339.73% | 42.65% | |||
| Normalized Diluted EPS | -289.42% | 42.64% | |||
| Average Basic Shares Outstanding | -1.17% | -4.47% | |||
| Average Diluted Shares Outstanding | -1.17% | -4.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||